HK1208225A1 - Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1 - Google Patents
Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1Info
- Publication number
- HK1208225A1 HK1208225A1 HK15108922.9A HK15108922A HK1208225A1 HK 1208225 A1 HK1208225 A1 HK 1208225A1 HK 15108922 A HK15108922 A HK 15108922A HK 1208225 A1 HK1208225 A1 HK 1208225A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- positive allosteric
- receptor positive
- allosteric modulators
- aryl methyl
- methyl benzoquinazolinone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23845709P | 2009-08-31 | 2009-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208225A1 true HK1208225A1 (en) | 2016-02-26 |
Family
ID=43628378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15108922.9A HK1208225A1 (en) | 2009-08-31 | 2015-09-11 | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8846702B2 (es) |
| EP (2) | EP2473048B1 (es) |
| JP (1) | JP5658255B2 (es) |
| KR (1) | KR101651312B1 (es) |
| CN (1) | CN102480964B (es) |
| AU (1) | AU2010286683B9 (es) |
| BR (1) | BR112012003464B8 (es) |
| CA (1) | CA2770480C (es) |
| CO (1) | CO6501188A2 (es) |
| CY (1) | CY1116452T1 (es) |
| DK (1) | DK2473048T3 (es) |
| ES (1) | ES2537979T3 (es) |
| HK (1) | HK1208225A1 (es) |
| HR (1) | HRP20150572T1 (es) |
| HU (1) | HUE026296T2 (es) |
| IL (1) | IL217638A (es) |
| ME (1) | ME02151B (es) |
| MX (1) | MX2012002583A (es) |
| MY (1) | MY160075A (es) |
| NZ (1) | NZ598462A (es) |
| PL (1) | PL2473048T3 (es) |
| PT (1) | PT2473048E (es) |
| RS (1) | RS54051B1 (es) |
| RU (1) | RU2507204C2 (es) |
| SI (1) | SI2473048T1 (es) |
| WO (1) | WO2011025851A1 (es) |
| ZA (1) | ZA201201205B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9199939B2 (en) | 2009-12-17 | 2015-12-01 | Merck Sharp & Dohme Corp. | Quinoline amide M1 receptor positive allosteric modulators |
| WO2011159553A1 (en) | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| EP2582676B1 (en) | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| WO2012158473A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
| US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
| US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| EP3313836B1 (en) * | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| ES2750868T3 (es) * | 2015-09-10 | 2020-03-27 | Suven Life Sciences Ltd | Derivados de fluoroindol como moduladores alostéricos positivos del receptor muscarínico M1 |
| US10548899B2 (en) | 2015-10-20 | 2020-02-04 | Takeda Pharmaceutical Company Limited | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity |
| WO2017151449A1 (en) * | 2016-03-04 | 2017-09-08 | Merck Sharp & Dohme Corp. | M1 receptor positive allosteric modulator compounds and methods of use thereof |
| WO2018194181A1 (en) * | 2017-04-18 | 2018-10-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
| KR20210068025A (ko) | 2018-09-28 | 2021-06-08 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003A (en) * | 1851-03-25 | Improvement in scythe-tastenings | ||
| RU2167877C2 (ru) | 1995-05-31 | 2001-05-27 | Эйсай Ко., Лтд. | Производные конденсированных полициклических гетероциклических соединений и способ их получения |
| CZ304203B6 (cs) | 1999-04-30 | 2014-01-02 | Pfizer Products Inc. | Modulátor glukokortikoidního receptoru a léčivo pro léčbu zánětlivé choroby s jeho obsahem |
| WO2001087845A2 (en) * | 2000-05-15 | 2001-11-22 | Fujisawa Pharmaceutical Co., Ltd. | N-containing heterocyclic compounds and their use as 5-ht antagonists |
| US20060233843A1 (en) | 2003-02-19 | 2006-10-19 | Conn P J | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| CA2655787A1 (en) * | 2006-06-28 | 2008-01-03 | Merck And Co., Inc. | Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
| ES2400695T3 (es) * | 2006-07-17 | 2013-04-11 | Amgen Inc. | Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38 |
| CN104211684A (zh) | 2007-09-26 | 2014-12-17 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
| CN102292323B (zh) * | 2008-11-20 | 2014-12-24 | 默沙东公司 | 芳基甲基苯并喹唑啉酮 m1受体正向变构调节剂 |
| EP2398324B1 (en) * | 2009-02-23 | 2014-09-03 | Merck Sharp & Dohme Corp. | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
| US8293744B2 (en) | 2009-04-20 | 2012-10-23 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators |
| EP2483275B1 (en) | 2009-10-01 | 2014-10-15 | Merck Sharp & Dohme Corp. | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
| EP2490692B1 (en) | 2009-10-21 | 2016-11-16 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| EP2512245B1 (en) | 2009-12-14 | 2014-07-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| GB0921949D0 (en) | 2009-12-16 | 2010-02-03 | Fujifilm Mfg Europe Bv | Curable compositions and membranes |
| US8507494B2 (en) | 2010-04-30 | 2013-08-13 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived M1 receptor positive allosteric modulators |
-
2010
- 2010-08-26 BR BR112012003464A patent/BR112012003464B8/pt active IP Right Grant
- 2010-08-26 HU HUE10812601A patent/HUE026296T2/en unknown
- 2010-08-26 CN CN201080038600.7A patent/CN102480964B/zh active Active
- 2010-08-26 ES ES10812601.2T patent/ES2537979T3/es active Active
- 2010-08-26 RS RS20150383A patent/RS54051B1/en unknown
- 2010-08-26 ME MEP-2015-86A patent/ME02151B/me unknown
- 2010-08-26 JP JP2012526961A patent/JP5658255B2/ja active Active
- 2010-08-26 DK DK10812601.2T patent/DK2473048T3/en active
- 2010-08-26 WO PCT/US2010/046733 patent/WO2011025851A1/en active Application Filing
- 2010-08-26 MX MX2012002583A patent/MX2012002583A/es active IP Right Grant
- 2010-08-26 NZ NZ598462A patent/NZ598462A/xx not_active IP Right Cessation
- 2010-08-26 CA CA2770480A patent/CA2770480C/en active Active
- 2010-08-26 PL PL10812601T patent/PL2473048T3/pl unknown
- 2010-08-26 EP EP10812601.2A patent/EP2473048B1/en active Active
- 2010-08-26 PT PT108126012T patent/PT2473048E/pt unknown
- 2010-08-26 MY MYPI2012000722A patent/MY160075A/en unknown
- 2010-08-26 EP EP15159929.7A patent/EP2915812A1/en not_active Withdrawn
- 2010-08-26 KR KR1020127005167A patent/KR101651312B1/ko active IP Right Grant
- 2010-08-26 US US13/392,647 patent/US8846702B2/en active Active
- 2010-08-26 RU RU2012112064/04A patent/RU2507204C2/ru active
- 2010-08-26 SI SI201030940T patent/SI2473048T1/sl unknown
- 2010-08-26 AU AU2010286683A patent/AU2010286683B9/en not_active Ceased
-
2012
- 2012-01-19 IL IL217638A patent/IL217638A/en not_active IP Right Cessation
- 2012-02-17 ZA ZA2012/01205A patent/ZA201201205B/en unknown
- 2012-02-24 CO CO12033021A patent/CO6501188A2/es active IP Right Grant
-
2015
- 2015-05-28 HR HRP20150572TT patent/HRP20150572T1/hr unknown
- 2015-06-19 CY CY20151100527T patent/CY1116452T1/el unknown
- 2015-09-11 HK HK15108922.9A patent/HK1208225A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1208225A1 (en) | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1 | |
| ZA201103612B (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| EP2490692A4 (en) | COMPOUNDS OF QUINOLÉINONE-PYRAZOLONE POSITIVE ALLOSTERIC MODULATORS OF THE M1 RECEPTOR | |
| HK1232219A1 (zh) | 作為趨化因子受體調節劑的硫衍生物 | |
| EP2588104A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF ISOINDOLONE M1 RECEIVER | |
| EP2512245A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF PYRIDOQUINAZOLINONE M1 RECEPTORS | |
| EP2624697A4 (en) | POSITIVE ALLOSTERIC DIHYDROBENZOCHINAZOLINONE M1 RECEPTOR MODULATORS | |
| EP2501231A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE QUINOLIZIDINONE-CARBOXAMIDE TYPE M1 RECEPTOR | |
| EP2515656A4 (en) | POSITIVE ALLOSTERIC AMINOBENZOCHINAZOLINONE M1 RECEPTOR MODULATORS | |
| HK1170122A1 (zh) | 喹啉酰胺 受體陽性的别構調節劑 | |
| EP2244577A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF M1 RECEIVER OF QUINOLIZIDINONE TYPE | |
| EP2312949A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF M1 N-HETEROCYCLIC RECEPTOR | |
| HK1171449A1 (en) | Morpholinothiazoles as alpha positive allosteric modulators | |
| EP2582241A4 (en) | HETEROCYCLIC FUSIONED PHENANTHROLINONE COMPOUNDS USEFUL AS POSITIVE ALLOSERIC MODULATORS OF THE M1 RECEPTOR | |
| ZA201404270B (en) | Dosage regimen of an s1p receptor modulator | |
| EP2252151A4 (en) | POSITIVE ALLOSTERIC CHINOLIZIDINONE M1 RECEPTOR MODULATORS | |
| EP2421366A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF A HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR | |
| GB201004739D0 (en) | Receptor modulators | |
| EP2563126A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF M1 RECEPTOR DERIVED FROM HETEROCYCLIC QUINOLIZINE | |
| EP2709451A4 (en) | POSITIVE ALLOSTERIC N-NETWORKED LACTAM M1 RECEPTOR MODULATORS | |
| EP2709621A4 (en) | POSITIVE ALLOSERIC MODULATORS OF M1 RECEPTOR TO QUINOLINE-AMIDE N-BINDING | |
| EP2355659A4 (en) | M1 RECEPTOR MODULATORS CONCEALED HETEROCYCLIC POSITIVE ALLOSTERIC | |
| ZA201303950B (en) | Glucagon receptor modulators | |
| EP2252299A4 (en) | CONDENSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | |
| EP2340247A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE CHINOLIZIDINONE M1 RECEPTOR |